Skip to main content
Premium Trial:

Request an Annual Quote

Genaissance to Identify Genetic Markers of Patients Responding to Merck Antidepressant

Click herefor an updated version of this story.


NEW YORK, Sept. 23 (GenomeWeb News) - Genaissance will use its haplotyping technology to find genetic markers identifying patients that respond to a Merck selective seratonin inhibitor, and will develop and commercialize the drug as part of a license agreement penned by the two companies, Merck said today in a press release.


During the first half of 2005, Genaissance hopes to begin enrollment for a Phase II clinical trial that will include pharmacogenomic characterization of patients, said the statement.


Under the terms of the agreement, Merck is entitled to receive up to $44 million worth of common shares of Genaissance for the initial license fee and milestone payments up to the first commercial sale, based on a trailing average of the closing price of the stock prior to the relevant payment dates, said the statement.  


The compound, vilazodone, is also a 5HT1A partial agonist, said Merck.  In Phase II clinical trials for depression, the compound has shown signals of efficacy and a favorable side effects profile in more than 1,000 patients, the company added.

The Scan

Mosquitos Genetically Modified to Prevent Malaria Spread

A gene drive approach could be used to render mosquitos unable to spread malaria, researchers report in Science Advances.

Gut Microbiomes Allow Bears to Grow to Similar Sizes Despite Differing Diets

Researchers in Scientific Reports find that the makeup of brown bears' gut microbiomes allows them to reach similar sizes even when feasting on different foods.

Finding Safe Harbor in the Human Genome

In Genome Biology, researchers present a new approach to identify genomic safe harbors where transgenes can be expressed without affecting host cell function.

New Data Point to Nuanced Relationship Between Major Depression, Bipolar Disorder

Lund University researchers in JAMA Psychiatry uncover overlapping genetic liabilities for major depression and bipolar disorder.